CCL2 and Alzheimer disease: This finding was confirmed in a longitudinal study, where CSF MCP-1 levels were significantly elevated in prodromal Alzheimer’s disease patients when compared to controls and associated with faster cognitive decline and development of dementia within a shorter time period [157] (Table 2).